Alexion Pharmaceuticals Inc. (ALXN) Release: New Data Presented At American Society of Hematology Annual Meeting Enhance Understanding Of PNH And aHUS To Provide Optimal Care for Patients With These Life-threatening Disorders
12/9/2013 7:26:18 AM
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soliris® (eculizumab) treatment in patients with atypical hemolytic uremic syndrome (aHUS) as well as new patient registry data providing further insight into optimal care for patients with paroxysmal nocturnal hemoglobinuria (PNH) at the American Society of Hematology (ASH) 55th Annual Meeting and Exposition in New Orleans. Data included:
Help employers find you! Check out all the jobs and post your resume.
comments powered by